The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | The current guidelines and therapies for TP53-mutated MDS and AML
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses current guidelines and therapies for TP53-mutated myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). He proposes that TP53-mutated disease should be treated as a distinct entity, including all patients with over 5% blasts, multi-hit, or complex karyotype. The current standard of care (SoC) involves hypomethylating agents (HMA), venetoclax, and stem cell transplantation (SCT). However, Dr Sallman strongly advocates for enrolling all patients in clinical trials. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
